EU/3/05/270: Orphan designation for the treatment of renal-cell carcinoma

Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex

Table of contents


On 11 April 2005, orphan designation (EU/3/05/270 was granted by the European Commission to Antigenics Therapeutics Limited, Ireland, for autologous tumor derived gp96 heat shock proteinpeptide complex for the treatment of renal cell carcinoma.

Key facts

Active substance
Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex
Intended use
Treatment of renal-cell carcinoma
Orphan designation status
EU designation number
Date of designation
Antigenics Therapeutics Limited
25/28 North Wall Quay
Dublin 1
Telephone: +353 1 649 2000
Telefax: +353 1 649 2649

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating